|Maine Medicine Weekly E-Update, July 20, 2022
Novavax COVID-19 Vaccine Authorized by FDA & CDC
The Food and Drug Administration (FDA) last week approved an emergency use authorization (EUA) for the Novavax COVID-19 vaccine, bringing a fourth vaccine to help against the backdrop of a BA.5 Omicron subvariant surge and lagging vaccine and booster dose uptake.
Earlier this week, Centers for Disease Control and Prevention Director Rochelle Walensky endorsed the Novavax COVID-19 vaccine following a 12-0 vote recommending the traditional protein-based shot by the agency's Advisory Committee on Immunization Practices (ACIP). Novavax's vaccine will hit the market in the coming weeks.
Emergency use of the Novavax COVID-19 vaccine is for individuals 18 years of age and older. The vaccine is authorized for emergency use as a two-dose primary series, given three weeks apart.
The vaccine will be permitted to be given to adults as a primacy immunization series, limiting its use given roughly two-thirds of people have already received their initial shots. However, the vaccine may be a good option for those allergic to components of the messenger RNA vaccines developed by Pfizer-BioNTech and Moderna.
The Biden administration has bought 3.5 million doses of the vaccine, which is administered in a two-dose series given 3 to 8 weeks apart. Those with moderate or severe immune compromise should receive the doses 3 weeks apart.
For More Information< Previous Article | Next Article >
[ return to top ]
ensure delivery of Maine Medicine Weekly Update,
please add 'firstname.lastname@example.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm
For more information or to contact us directly, please visit www.mainemed.com | ©